Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MPI | P34949 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11049508 | 0.91 | LTA4H (0.47) | ALDH1A1LMNALTA4HSMN1; SMN2POLB | |
| SCHEMBL6965891 | 0.75 | ALDH1A1 (0.42) | ALDH1A1LMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL6965898 | 0.75 | GRIN2B (0.55) | MAPT | |
| SCHEMBL2103486 | 0.74 | FGFR1 (0.50) | LTA4HPOLB | |
| SCHEMBL11050091 | 0.73 | LPL (0.36) | ALDH1A1LMNAMAPTSMN1; SMN2CYP2D6 | |
| SCHEMBL14076160 | 0.73 | LTA4H (0.57) | PTGIRALDH1A1LMNAMAPTHTT | |
| SCHEMBL6972732 | 0.73 | NOTUM (0.39) | ALDH1A1HTTLTA4HPOLB | |
| SCHEMBL2626824 | 0.71 | HRH3 (0.60) | PTGIRMAPTSMN1; SMN2POLB | |
| SCHEMBL7971472 | 0.71 | HRH3 (0.48) | ALDH1A1LMNAMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL7988592 | 0.70 | TDP1 (0.45) | ALDH1A1LMNAMAPTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
| US-8158668-B2 | Methods for treating CNS disorders with 4-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1981880-B1 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | CRY1, GPR119, MTNR1A | PTGIR 1416/4885ALDH1A1 351/4885LMNA 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.